401 related articles for article (PubMed ID: 30974127)
1. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
Beigel JH; Nam HH; Adams PL; Krafft A; Ince WL; El-Kamary SS; Sims AC
Antiviral Res; 2019 Jul; 167():45-67. PubMed ID: 30974127
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.
McKimm-Breschkin JL; Jiang S; Hui DS; Beigel JH; Govorkova EA; Lee N
Antiviral Res; 2018 Jan; 149():118-142. PubMed ID: 29162476
[TBL] [Abstract][Full Text] [Related]
3. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
McKimm-Breschkin JL; Fry AM
Antiviral Res; 2016 May; 129():21-38. PubMed ID: 26872862
[TBL] [Abstract][Full Text] [Related]
4. Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.
Hurt AC; Hui DS; Hay A; Hayden FG
Influenza Other Respir Viruses; 2015 Jan; 9(1):20-31. PubMed ID: 25399715
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
[TBL] [Abstract][Full Text] [Related]
10. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
11. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
12. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
McKimm-Breschkin JL; Hay AJ; Cao B; Cox RJ; Dunning J; Moen AC; Olson D; Pizzorno A; Hayden FG
Antiviral Res; 2022 Jan; 197():105227. PubMed ID: 34933044
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir: First Approval.
Lamb YN
Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
[TBL] [Abstract][Full Text] [Related]
16. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
17. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.
Hickman MR; Saunders DL; Bigger CA; Kane CD; Iversen PL
PLoS Negl Trop Dis; 2022 Mar; 16(3):e0010220. PubMed ID: 35259154
[TBL] [Abstract][Full Text] [Related]
18. Halting coronavirus polymerase.
Kirchdoerfer RN
J Biol Chem; 2020 Apr; 295(15):4780-4781. PubMed ID: 32277065
[TBL] [Abstract][Full Text] [Related]
19. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.
Brown AJ; Won JJ; Graham RL; Dinnon KH; Sims AC; Feng JY; Cihlar T; Denison MR; Baric RS; Sheahan TP
Antiviral Res; 2019 Sep; 169():104541. PubMed ID: 31233808
[TBL] [Abstract][Full Text] [Related]
20. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
